Page last updated: 2024-11-05

doxifluridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

doxifluridine : A pyrimidine 5'-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5' position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluorouracil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID18343
CHEMBL ID1130
CHEBI ID31521
SCHEMBL ID8094
MeSH IDM0083927
PubMed CID12798016
MeSH IDM0083927

Synonyms (102)

Synonym
MLS002207077
MLS002172440
smr000326811
1-((4s,2r,3r,5r)-3,4-dihydroxy-5-methyloxolan-2-yl)-5-fluoro-1,3-dihydropyrimidine-2,4-dione
1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyl-tetrahydrofuran-2-yl]-5-fluoro-pyrimidine-2,4-dione
furtulon
5-dfur
ro-21-9738
EU-0100537
5-fluoro-5'-deoxyuridine ,
LOPAC0_000537
doxifluridine
5'-deoxy-5-fluorouridine
MLS001332579
MLS001332580
NCGC00093926-03
D01309
doxifluridine (jp17/inn)
furtulon (tn)
doxifluridinum [inn-latin]
flutron
5'-doxifluridine
uridine, 5'-deoxy-5-fluoro-
uridine-5'-deoxy-5-fluoro-
ro 219738
einecs 221-440-1
doxifluridine [inn:jan]
5'-dfur
1-(beta-d-5-desoxyribofuranoxyl)-5-fluoruracil
doxifluridina [inn-spanish]
ro 21-9738
NCGC00093926-02
NCGC00093926-01
5'fdur
HMS2090C22
5'dfurd
F 8791
bdbm50132295
5''-deoxy-5-fluorouridine (5''-dfur)
1-((2r,5r)-3,4-dihydroxy-5-methyl-tetrahydro-furan-2-yl)-5-fluoro-1h-pyrimidine-2,4-dione
1-((2r,3r,4s,5r)-3,4-dihydroxy-5-methyl-tetrahydrofuran-2-yl)-5-fluoropyrimidine-2,4(1h,3h)-dione
ro-219738
CHEMBL1130 ,
chebi:31521 ,
nsc-758890
fulturon
HMS3261L15
doxifluridinum
v1jk16y2jp ,
doxifluridina
unii-v1jk16y2jp
nsc 758890
tox21_111231
dtxcid602967
cas-3094-09-5
dtxsid2022967 ,
CCG-204627
HMS2231I05
HY-B0021
CS-1270
LP00537
S2045
AKOS015852921
AKOS015896821
1-(.beta.-d-5-desoxyribofuranoxyl)-5-fluoruracil
doxifluridine [jan]
doxifluridine [inn]
doxifluridine [mart.]
doxifluridine [who-dd]
doxifluridine [mi]
SCHEMBL8094
tox21_111231_1
NCGC00093926-05
KS-5065
SRI-11552-08
tox21_500537
NCGC00261222-01
ZWAOHEXOSAUJHY-ZIYNGMLESA-N
1-((2r,3r,4s,5r)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoropyrimidine-2,4(1h,3h)-dione
SRI-11552_09
amc 0101
SR-01000075886-1
sr-01000075886
capecitabine impurity b, european pharmacopoeia (ep) reference standard
5-fluoro-5`-deoxyuridine
SR-01000075886-5
1-(5-deoxy-beta-d-ribofuranosyl)-5-fluoropyrimidine-2,4(1h,3h)-dione (5'-deoxy-5-fluorouridine)
DB12947
Q1253473
AMY13408
capecitabine impurity b (usp)
BRD-K58262659-001-09-7
SDCCGSBI-0050520.P002
NCGC00093926-11
furtulon, flutron, doxyfluridine, doxifluridina, doxifluridinum 5'-doxifluridine, 5'dfurd, 5-fluoro-5'-deoxyuridine
BP-58654
3094-09-5
NCGC00093926-04
1-[(2s,3s,4r,5s)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl]-5-fluoropyrimidine-2,4(1h,3h)-dione
mfcd00866530
5'-desoxy-5-fluorouridin
1-[(2r,3r,4r,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoropyrimidine-2,4-dione

Research Excerpts

Overview

Doxifluridine (5'-DFUR) is an anticancer drug converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) It has shown activity on a variety of solid tumours.

ExcerptReferenceRelevance
"Doxifluridine (5'-DFUR) is an intermediate of capecitabine approved in Europe and USA to treat metastatic colorectal cancer."( A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines.
Koda, K; Kodaira, S; Miyazaki, M; Nakazato, H; Ogawa, K; Saito, N; Sarashina, H; Suwa, T; Suzuki, M; Watanabe, S, 2003
)
1.04
"Doxifluridine (5'-DFUR) is an anticancer drug converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP). "( Thymidine phosphorylase expression correlates with malignant potential and anti-tumor effect of doxifluridine on gastric cancer: multivariate analysis for adjuvant chemotherapy doxifluridine vs. 5-fluorouracil.
Ishii, R; Koda, K; Miyazaki, M; Oda, K; Takiguchi, N,
)
1.79
"Doxifluridine is a new fluoropyrimidine derivative, that is converted into fluorouracil, its active component."( Doxifluridine: an active agent in advanced gastrointestinal cancer.
Bajetta, E; Buzzoni, R; Di Bartolomeo, M; Somma, L,
)
2.3
"Doxifluridine is a fluoropyrimidine derivative and is activated to 5-fluorouracil by uridine phosphorylase, which is more highly expressed in malignant cells."( Oral doxifluridine in elderly patients with metastatic colorectal cancer: a multicenter phase II study.
Barduagni, M; Bertuccelli, M; Calabresi, F; Carrai, M; Ceribelli, A; Cianci, C; De Marco, S; Falcone, A; Pfanner, E; Ricci, S, 1994
)
1.52
"Doxifluridine is a novel 5-fluorouracil (5-FU) prodrug which is transformed into 5-FU in neoplastic tissue."( A phase I-II study of oral doxifluridine plus radiotherapy in radiosensitive tumors of the pelvic region.
Conte, PF; Ducci, F; Falcone, A; Laddaga, M; Pandolfi, A; Spagnesi, S; Stampino, CG, 1993
)
1.3
"Doxifluridine (dFUR) is a fluoropyrimidine derivative that has shown activity on a variety of solid tumours. "( Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer.
Amadori, D; Bajetta, E; Calabresi, F; Colleoni, M; Comella, G; Lorusso, V; Marangolo, M; Rosso, R; Scanni, A; Sobrero, A, 1993
)
1.97
"Doxifluridine (d-FUR) is a fluoropyrimidine derivative that is converted into 5-FU inside tumor cells, where it is selectively cytotoxic."( Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients.
Bajetta, E; Bandieri, E; Buzzoni, R; Carnaghi, C; Del Vecchio, M; Di Bartolomeo, M; Gallo Stampino, C; Somma, L,
)
2.3
"Doxifluridine (5-dFUR) is a fluoropyrimidine derivative that has been shown to be active on a variety of solid tumors. "( Randomized phase II noncomparative trial of oral and intravenous doxifluridine plus levo-leucovorin in untreated patients with advanced colorectal carcinoma.
Bajetta, E; Bordogna, G; Comella, G; Di Bartolomeo, M; Gebbia, V; Moreschi, M; Scanni, A; Somma, L; Stampino, CG; Turci, D, 1996
)
1.97
"Doxifluridine is a fluoropyrimidine derivate which can be administered orally with very low toxicities."( Phase II study of oral doxifluridine in elderly patients with advanced non-small-cell lung cancer.
Baldini, E; Ceribelli, A; Comella, G; Conte, PF; Falcone, A; Pfanner, E; Ricci, S; Sarcina, R; Stampino, CG; Tibaldi, C, 1996
)
1.33
"Doxifluridine (5-dFUR) is a fluoropyrimidine derivative, which is preferentially converted to 5-fluorouracil (5-FU) within tumour tissues. "( Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens.
Artale, S; Bajetta, E; Bignami, P; Buzzoni, R; Del Vecchio, M; Di Bartolomeo, M; Magnani, E; Somma, L; Zunino, F, 1997
)
3.18
"Doxifluridine is a new fluoropyrimidine that has excellent absorption by the gastrointestinal tract when given orally. "( Pharmacokinetics of oral doxifluridine in patients with colorectal cancer.
Bajetta, E; Colleoni, M; de Braud, F; Guenzi, A; Stampino, CG; Zampino, MG,
)
1.88
"Doxifluridine (5-dFUR) is a 5-fluorouracil (5-FU) prodrug that is transformed into 5-FU in neoplastic tissue, which suggests that it may improve the activity of radiotherapy."( Integrated treatment with doxifluridine and radiotherapy in recurrent or primary unresectable rectal cancer. A feasibility study.
Artale, S; Bajetta, E; Bozzetti, F; Buzzoni, R; Di Bartolomeo, M; Valvo, F,
)
1.15
"Doxifluridine (5-DFUR) is an orally active fluoropyrimidine, and its cytotoxic metabolite (5-FU) may concentrate in areas of high tumor vascularization."( Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study.
Artale, S; Bajetta, E; Bozzetti, F; Buzzoni, R; Di Bartolomeo, M; Mazzaferro, V; Ricci, SB; Stani, SC; Toffolatti, L, 1999
)
1.02
"Doxifluridine is an oral fluoropyrimidine derivative activated to 5-fluorouracil by uridine phosphorylase which is more expressed in malignant cells."( Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study.
Allegrini, G; Bartolozzi, C; Brunetti, I; Conte, PF; Di Marsico, R; Falcone, A; Fontana, E; Lencioni, M; Masi, G; Orlandini, C; Pfanner, E; Stampino, CG, 2000
)
1.54
"Doxifluridine (5'-dFUR) is a prodrug of 5 fluorouracil (5-FU) synthesized in an attempt to improve the therapeutic index compared with 5-FU. "( A phase I study of doxifluridine as a five-day stepped-dose continuous infusion.
Bishop, JF; Guentert, TW; Hillcoat, BL; Morris, RG; Olver, IN; Reece, PA, 1990
)
2.05
"Doxifluridine is an active agent in colorectal cancer."( A randomized comparison of doxifluridine and fluorouracil in colorectal carcinoma.
Alberto, P; Cavalli, F; Germano, G; Joss, R; Kaplan, S; Martz, G; Mermillod, B; Spati, B; Weber, W, 1988
)
1.29

Effects

Doxifluridine has therapeutic activity, albeit limited, in advanced rectosigmoid adenocarcinoma. It has no useful activity against malignant melanoma.

ExcerptReferenceRelevance
"Doxifluridine has therapeutic activity, albeit limited, in advanced rectosigmoid adenocarcinoma."( Phase II study of doxifluridine in advanced colorectal adenocarcinoma.
Abele, R; Alberto, P; Cavalli, F; Hartmann, D; Hofmann, V; Holdener, EE; Kaplan, S; Ryssel, HJ; Siegenthaler, P, 1983
)
1.32
"Doxifluridine has no useful activity against malignant melanoma."( Phase II study of 5'-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma.
Alberto, P; Bruntsch, U; Cavalli, F; Clavel, M; Gundersen, S; Pinedo, H; Renard, J; Rozencweig, M; Siegenthaler, P, 1986
)
1.25

Treatment

ExcerptReferenceRelevance
"Treatment with doxifluridine at a dosage of 3000 mg/m2 given intravenously for 5 successive days at 3-week intervals led to 6 partial remissions (17%)."( Phase II clinical trial of doxifluridine in patients with advanced ovarian cancer.
Neijt, JP; ten Bokkel Huinink, WW; van der Burg, ME; van Oosterom, AT; Vermorken, JB; Willemse, PH, 1991
)
0.92

Toxicity

ExcerptReferenceRelevance
" The administration of 5'-DFUR resulted in damage to the intestinal mucosal membrane and diarrhea in normal mice, whereas Ro 09-1390 was much less toxic to the intestinal tract."( Comparative antitumor activity and intestinal toxicity of 5'-deoxy-5-fluorouridine and its prodrug trimethoxybenzoyl-5'-deoxy-5-fluorocytidine.
Eda, H; Fujimoto, K; Ishida, M; Ishitsuka, H; Miwa, M; Ninomiya, Y; Sahara, H; Umeda, I; Yokose, K, 1990
)
0.28
" However, a WHO grade 4 hematologic toxicity was observed in 9 patients, and 2 toxic deaths were related to severe granulocytopenia and sepsis."( [Doxifluridine toxicity, a fluorouracil analog with low myelosuppressive effect].
Alberto, P; Mermillod, B; Winkelmann, JJ, 1990
)
1.19
" FdUrd, in particular, had a very minor effect on rRNA production even at very toxic drug concentrations."( Correlation between ribosomal RNA production and RNA-directed fluoropyrimidine cytotoxicity.
Armstrong, RD; Cadman, EC; Takimoto, CH; Tan, YY, 1987
)
0.27
" 5'-DFUR was less toxic to immune organs and the functions than those by other fluorinated pyrimidines."( [Antitumor activity and toxicity to the immune system and intestine, of the fluorinated pyrimidines FUra, 5'-DFUR, tegafur and UFT].
Fujimoto, K; Ishitsuka, H; Matsuura, N; Miwa, M; Ninomiya, Y; Ryu, M, 1988
)
0.27
" With use of these studies, a therapeutic ratio (concentration that prevented 25% clonal growth compared to untreated control of bone marrow divided by LD50 of tumor) was calculated for each drug in each tumor."( 5'-Deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow.
Armstrong, RD; Cadman, E, 1983
)
0.27
" The results indicate that immunotoxic profiles of Ro 09-1390 and 5'-DFUR are very similar and characterized primarily by myelotoxicity and Ro 09-1390 is approximately two-times less toxic than 5'-DFUR on a molar basis in BDF1 mice."( Comparative immunotoxicity assessment of N4-Trimethoxybenzoyl-5'-deoxy-5- fluorocytidine (Ro 09-1390) and 5'-deoxy-5-fluorouridine (5'-DFUR) in BDF1 mice.
Anderson, TD; Hayes, TJ; Horii, I; Inoue, T, 1996
)
0.29
" Therapeutic safety was evaluated by analyses of adverse events with the recommended dose."( [Evaluation of safety and efficacy for bi-weekly Docetaxel and 5'-DFUR combination therapy in patients with advanced or recurrent breast cancer--Phase I study].
Ikeda, M; Ishiguro, K; Kataoka, T; Komaki, K; Kurebayashi, J; Morimoto, T; Sonoo, H; Tanaka, K; Tangoku, A; Yoshizawa, K, 2006
)
0.33
" No DLT was observed in level 2, and this combination therapy seemed safe and feasible for outpatients."( [Evaluation of safety and efficacy for bi-weekly Docetaxel and 5'-DFUR combination therapy in patients with advanced or recurrent breast cancer--Phase I study].
Ikeda, M; Ishiguro, K; Kataoka, T; Komaki, K; Kurebayashi, J; Morimoto, T; Sonoo, H; Tanaka, K; Tangoku, A; Yoshizawa, K, 2006
)
0.33
" Capecitabine was less toxic in monkeys than oral 5'-DFUR according to dose (mmol/kg) and 5'-DFUR AUC."( Relationship between AUC of 5'-DFUR and toxicity of capecitabine, fluoropyrimidine carbamate analogs, and 5'-DFUR in monkeys, mice, and rats.
Horii, I; Kawashima, A; Kobayashi, K; Nakano, K; Shindoh, H; Shishido, N, 2006
)
0.33
" We present a colon cancer patient with the UGT1A1 polymorphism (UGT1A1 *28) as a known high risk for irinotecan, who was treated with a combination of doxifluridine and irinotecan for peritoneal dissemination resulting in stable disease for 2 years without adverse reactions, although the patient initially developed severe adverse effects to the combination of the protracted venous infusion of 5-FU and irinotecan."( Irinotecan cytotoxicity does not necessarily depend on the UGT1A1 polymorphism but on fluoropyrimidine: a molecular case report.
Hiro, J; Inoue, Y; Kusunoki, M; Miki, C; Nakatani, K; Nobori, T; Ojima, E; Toiyama, Y; Watanabe, H, 2006
)
0.53

Pharmacokinetics

Capecitabine can be given at a higher dose, and therefore is expected to yield higher antitumor activity, than doxifluridine.

ExcerptReferenceRelevance
"5'-Deoxy-5-fluorouridine (DFUR), whether or not combined with (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) was pursued in BDF1 mice from both a pharmacokinetic viewpoint, following a single oral dose administration, and an anticancer viewpoint, following 5 daily oral doses in mice inoculated subcutaneously with adenocarcinoma 755 tumor cells."( Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels.
De Clercq, E; Hoshi, A; Iigo, M; Nakajima, Y; Nishikata, K; Odagiri, H; Okudaira, N, 1989
)
0.28
" The elimination half-life time for 5-FU was protracted by a factor of 2-3 compared with the direct injection of 5-FU."( Phase I/II tolerability/pharmacokinetic study with one-hour intravenous infusion of doxifluiridine (5'-dFUrd) 3 g/m2 VS 5 g/m2 QD x 5 per month.
Aas, M; Flokkmann, A; Fosså, SD; Heier, M; Heintz, R; Linder-Ciccolunghi, S; Moe, B, 1986
)
0.27
" The absorption and pharmacokinetic parameters of 5'-DFUR and its active metabolite 5-FU, after administration of 5'-DFUR in combination with AcyT, were evaluated in the animals."( Differential effects of acyclothymidine, a potent pyrimidine nucleoside phosphorylase inhibitor, on the pharmacokinetics of doxifluridine in rabbits via oral administration.
Fukushima, S; Hamada, A; Kawaguchi, T; Morinaga, A; Nakano, M; Saneyoshi, M, 1993
)
0.49
" It was expected that AcyT would only inhibit the phosphorolytic degradation of 5'-DFUR to 5-FU, but the effect was more evident on the pharmacokinetic parameters of 5-FU than on those of 5'-DFUR."( Modulation of the pharmacokinetics of 5'-deoxy-5-fluorouridine and 5-fluorouracil in rats by oral co-administration of acyclothymidine.
Fukushima, S; Hamada, A; Kawaguchi, T; Nakano, M; Saneyoshi, M; Shimizu, S, 1996
)
0.29
"A pharmacokinetic analysis program based on a tank-in-series model, MULTI(TIS), was developed for the evaluation of dose-dependency in the local disposition of a drug."( Pharmacokinetic analysis program based on tank-in-series model, MULTI(TIS), for evaluation of capacity-limited local disposition.
Fukumura, K; Higashimori, M; Nakagawa, T; Yamaoka, K, 1998
)
0.3
" None of the demographic or biologic parameters considered was significantly related to pharmacokinetic parameters."( Pharmacokinetics of oral doxifluridine in patients with colorectal cancer.
Bajetta, E; Colleoni, M; de Braud, F; Guenzi, A; Stampino, CG; Zampino, MG,
)
0.43
"A large interpatient pharmacokinetic variability was observed without any significant correlation with the clinical parameters studied."( Pharmacokinetics of oral doxifluridine in patients with colorectal cancer.
Bajetta, E; Colleoni, M; de Braud, F; Guenzi, A; Stampino, CG; Zampino, MG,
)
0.43
" The mean elimination half-life of intravenous dFUrd increased with the dose from 15 to 22 min."( Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients.
De Bruijn, EA; Highley, MS; Maes, RA; Reeuwijk, HJ; Tjaden, UR; Van Der Heyden, SA; Van Oosterom, AT; Van Slooten, H, 1999
)
0.3
" The ratio of FBAL to 5-FU in Cmax and AUC after dosing of UFT was the lowest among these four test compounds."( [Comparison of pharmacokinetics of 5-FU and alpha-fluoro-beta-alanine, a metabolite of 5-FU, in plasma after administration of UFT, tegafur, 5-FU or doxifluridine to rats].
Hirakawa, Y; Kawaguchi, Y; Kuwata, K; Matsushima, E; Nagayama, S, 2000
)
0.51
" Systemic exposure based on plasma concentrations of capecitabine and its metabolites was determined using individual parameter estimates derived from a population pharmacokinetic model constructed for this purpose in NONMEM."( Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
Blesch, KS; Burger, HU; Gieschke, R; Reigner, B; Steimer, JL, 2003
)
0.32
" Pharmacokinetic studies after administration of S-1 revealed high and prolonged plasma 5-FU levels."( S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study.
Ajani, JA; Itoh, N; Itoi, H; Shirasaka, T; Ueda, Y; Yamagishi, H; Yamashita, T, 2004
)
0.32
" Following treatment with 5'-DFUR, the median AUC and Cmax of 5'-DFUR tended to be higher in patients with a partial response (3."( Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).
Ebi, H; Igarashi, T; Kawada, K; Minami, H; Saeki, T; Sasaki, Y; Sigeoka, Y; Ueda, R; Usubuchi, N, 2005
)
0.33
"Forty patients and 75 pharmacokinetic time-courses were available for analysis."( Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
Lokiec, F; Rezaí, K; Urien, S, 2005
)
0.33
" Due to these pharmacokinetic merits, capecitabine can be given at a higher dose, and therefore is expected to yield higher antitumor activity, than doxifluridine."( [Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR)].
Ebi, H; Minami, H, 2005
)
0.76
"The Hollow Fibre Assay (HFA) is usually applied as an early in vivo model for anti-cancer drug screening, but is potentially an excellent model for short-term in vivo pharmacodynamic studies."( The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
Peters, GJ; Prins, HJ; Temmink, OH; van Gelderop, E, 2007
)
0.34
" Although a traditional toxicity-based maximum tolerated dose was not achieved, the highest dosing cohort represented a biologically relevant dose of enzastaurin, on the basis of preclinical data and correlative pharmacodynamic biomarker assays of protein kinase Cbeta inhibition in peripheral blood mononucleocytes, in combination with a standard dose of capecitabine."( A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
Baldwin, J; Basche, M; Britten, CD; Camidge, DR; Darstein, C; Finn, RS; Gail Eckhardt, S; Gore, L; Holden, SN; Leong, S; Musib, L; O'Bryant, CL; Thornton, D, 2008
)
0.35
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The purpose of this study was to investigate the pharmacokinetic properties of doxifluridine and its two major metabolites, 5-FU, and 5-fluorouridine (5-FUrd), in beagle dogs following a single oral administration of 200 mg doxifluridine capsule (Furtulon(®))."( Pharmacokinetic analysis of doxifluridine and its metabolites, 5-fluorouracil and 5-fluorouridine, after oral administration in beagle dogs.
Baek, IH; Kim, MS; Kwon, KI; Lee, BY, 2013
)
0.91
"Nine patients treated with CCB and BVZ for advanced colorectal cancer entered this pharmacokinetic study."( Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.
Buchner, P; Czejka, M; Farkouh, A; Georgopoulos, A; Gruenberger, B; Scheithauer, W; Schueller, J, 2014
)
0.4
" After repeated cycles of BVZ no significant pharmacokinetic interaction was observed."( Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.
Buchner, P; Czejka, M; Farkouh, A; Georgopoulos, A; Gruenberger, B; Scheithauer, W; Schueller, J, 2014
)
0.4
"From the pharmacokinetic point of view and in agreement with numerous clinical study data, co-administration of BVZ with CCB appears to be safe and efficient."( Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.
Buchner, P; Czejka, M; Farkouh, A; Georgopoulos, A; Gruenberger, B; Scheithauer, W; Schueller, J, 2014
)
0.4
" The primary aim of this study was to develop a pharmacokinetic model for capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine (dFCR), 5'-deoxy-5-fluorouridine (dFUR), 5-FU, and fluoro-β-alanine (FBAL) using data from a heterogeneous population of cancer patients (n = 237) who participated in seven clinical studies."( Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
Beijnen, JH; Cats, A; de Vries, N; Deenen, MJ; Huitema, ADR; Jacobs, BAW; Joerger, M; Meulendijks, D; Rosing, H; Schellens, JHM, 2019
)
0.51

Compound-Compound Interactions

The antitumor activity of recombinant human interleukin 2 (rIL-2) in combination with 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR) against marine colon carcinoma 26 (Colon 26) was studied. The good response rate and long time to progression and overall survival time indicate its potential as a first-line or second-line treatment for advanced or recurrent breast cancer patients.

ExcerptReferenceRelevance
"A comparative study of 5'-DFUR 600 mg/day alone (C-arm) or in combination with TAM 30 mg/day (A-arm) or MPA 600 mg/day (B-arm) was carried out."( [A comparative study with 5'-DFUR alone or in combination with tamoxifen (TAM) or medroxyprogesterone acetate (MPA) for advanced or recurrent breast cancer].
Aikawa, T; Hirai, T; Kotsuma, Y; Maeura, Y; Miyauchi, K; Takatsuka, Y; Yayoi, E, 1992
)
0.28
"We investigated the antitumor activities of 5-fluorouracil (5-FU), 5'-deoxy-5-fluorouridine (5'-DFUR), 1-hexylcarbamoyl-5-fluorouracil (HCFU) and 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT-207) in combination with hyperthermia in vitro."( Comparative antitumor activity of 5-fluorouracil and its prodrugs in combination with hyperthermia in vitro.
Akazai, Y; Fuchimoto, S; Iwagaki, H; Matsubara, N; Orita, K; Shiiki, S; Watanabe, T, 1991
)
0.28
"The present study compared the antitumor activities of chemotherapy with 5-fluorouracil (5-FU) and with its prodrug 5'-deoxy-5-fluorouridine (5'-DFUR) in combination with radiotherapy on a solid colon 26 adenocarcinoma in the mouse."( Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma.
Ishikawa, T; Ishitsuka, H; Ohkawa, T; Tanaka, Y, 1989
)
0.28
" Four cycles of the regimen I drug combination failed to prolong life due to toxic side effects in every cancer line."( [Effects of alternating chemotherapy with 2 non-cross-resistant drug combinations on human alimentary and breast cancer xenografts in nude mice].
Fujita, F; Fujita, M; Inaba, H; Sakamoto, Y; Shimozuma, K; Taguchi, T; Yamauchi, T, 1987
)
0.27
"Antitumor effects of oral fluorinated pyrimidines including 5'-DFUR and their combination with recombinant interferon (rIFN) alpha A/D (Bgl) or cytostatics were investigated using various tumor models in mice."( [Antitumor effects of 5'-deoxy-5-fluorouridine (5'-DFUR) against various murine tumors in combination with recombinant interferon alpha or cytostatics].
Eda, H; Fukuda, H; Ishikawa, T; Ishitsuka, H; Matsuura, N; Miwa, M; Ninomiya, Y; Tanaka, Y, 1987
)
0.27
" The increase in lifespan (ILS) of mice treated with 5'-DFUR was augmented by the combination with guanosine or inosine in a dose-dependent fashion, and the maximum ILS was about 160% with the combination, while that in the case of 5'-DFUR alone was only 48% in the P388 leukemia system."( Potentiation of the chemotherapeutic action of 5'-deoxy-5-fluorouridine in combination with guanosine and related compounds.
Iigo, M; Ishitsuka, H; Miwa, M; Nitta, K, 1987
)
0.27
"Modulation of the therapeutic efficacy of cisplatin (CDDP) and 5-fluoro-2'-deoxyuridine (FdUrd) alone and in combination with N-phosphonacetyl-L-aspartate (PALA) was evaluated in mice bearing colon carcinoma (C-26) using a weekly intravenous (i."( Modulation of the antitumour activity of cisplatin alone and in combination with 5-fluoro-2'-deoxyuridine by N-phosphonacetyl-L-aspartate in murine colon carcinoma no. 26.
Cao, S; Durrani, FA; Mayhew, EG; Peters, GJ; Rustum, YM; Van Laar, JA, 1995
)
0.29
" Combination with high-dose 5'-DFUR and low-dose intra-hepatic arterial infusion of CDDP is considered a very effective chemotherapy which can be performed ambulatorily while maintaining the quality of life of patients with liver metastases of gastric cancer."( [Combination with intra-hepatic arterial infusion of low-dose cisplatin and oral administration of high-dose doxyfluridine in patients with liver metastases of gastric cancer].
Kikkawa, N; Kobayashi, K; Mishima, H; Shin, E; Takatsuka, Y; Tamaki, Y; Tono, T; Yagyu, T, 1994
)
0.29
"In vivo antitumor activity of pirarubicin (THP) and epirubucin (EPI) in combination with doxifluridine (5'-DFUR) and cisplatin (CDDP) were examined using mouse P388 leukemia."( Antitumor effects of pirarubicin and epirubicin in combination with doxifluridine and cisplatin against mouse P388 leukemia.
Agata, N; Hirano, S; Iguchi, H; Izumi, H; Mase, T; Takeuchi, T; Tone, H, 1995
)
0.75
"The antitumor activity of recombinant human interleukin 2 (rIL-2) in combination with 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR) against marine colon carcinoma 26 (Colon 26) was studied."( Antitumor effects of 5'-deoxy-5-fluorouridine in combination with recombinant human interleukin 2 on murine colon carcinoma 26.
Fujiwara, K; Gotoh, K; Houkan, T; Midoro, K; Ootsu, K; Yukishige, K, 1997
)
0.51
"To evaluate the antitumor efficacy against metastatic breast cancer of fluoropyrimidines alone and combined with other chemotherapeutic agents, we developed a murine model of breast cancer metastatic to the lung by orthotopically implanting MDA-MB-435S breast tumors into mice."( [Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung].
Fujioka, A; Fukushima, M; Nakagawa, F; Nukatsuka, M; Ohshimo, H, 2002
)
0.31
"We designed a new regimen to evaluate the efficacy and feasibility of weekly paclitaxel combined with orally administered 5'-DFUR therapy against advanced and recurrent gastric cancer."( [Experience of weekly paclitaxel combined with orally administered doxifluridine therapy for advanced and recurrent gastric cancer-preliminary study].
Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Tsubono, M; Yasumizu, R, 2005
)
0.56
" Although a traditional toxicity-based maximum tolerated dose was not achieved, the highest dosing cohort represented a biologically relevant dose of enzastaurin, on the basis of preclinical data and correlative pharmacodynamic biomarker assays of protein kinase Cbeta inhibition in peripheral blood mononucleocytes, in combination with a standard dose of capecitabine."( A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
Baldwin, J; Basche, M; Britten, CD; Camidge, DR; Darstein, C; Finn, RS; Gail Eckhardt, S; Gore, L; Holden, SN; Leong, S; Musib, L; O'Bryant, CL; Thornton, D, 2008
)
0.35
" The good response rate and long time to progression and overall survival time of this doxifluridine combined with weekly paclitaxel therapy indicate its potential as a first-line or second-line treatment for advanced or recurrent breast cancer patients."( Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trial.
Asaishi, K; Doi, T; Inaba, M; Kimura, M; Nishimura, R; Okamoto, Y; Okuyama, N; Takeuchi, H; Tamaki, N; Tominaga, T; Yanagita, Y, 2008
)
0.95
"The purpose of this article is to report the first case of markedly increased anticoagulant activity of warfarin when used in combination with doxifluridine, given as a replacement for capecitabine."( Increased anticoagulant activity of warfarin used in combination with doxifluridine.
Genda, T; Hori, S; Miki, A; Nakajima, M; Satoh, H; Sawada, Y; Suehira, M, 2010
)
0.8
" The antitumor and anti-angiogenic effects of metronomic doxifluridine (delivered via oral gavage) in combination with TNP-470 were evaluated in vivo."( Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts.
Choijamts, B; Emoto, M; Kawarabayashi, T; Miyamoto, S; Naganuma, Y; Nakajima, K; Ogata, S; Shirota, K, 2011
)
1
" The efficacy of weekly paclitaxel in combination with doxifluridine (5'-DFUR) in gastric cancer patients with malignant ascites was evaluated."( Weekly paclitaxel in combination with doxifluridine for peritoneally disseminated gastric cancer with malignant ascites.
Ishikawa, H; Iwazaki, S; Izumi, M; Kakinuma, S; Kamoshita, N; Kawate, S; Kobayashi, I; Kobayashi, J; Makita, F; Nakagami, K; Ohya, T; Okabe, T; Sakamoto, I; Sato, Y; Sunose, Y; Takeyoshi, I; Tanahashi, Y; Tomizawa, N; Yamada, T; Yoshinari, D, 2011
)
0.89
"Weekly paclitaxel in combination with doxifluridine is effective for gastric cancer patients with malignant ascites with an acceptable toxicity profile."( Weekly paclitaxel in combination with doxifluridine for peritoneally disseminated gastric cancer with malignant ascites.
Ishikawa, H; Iwazaki, S; Izumi, M; Kakinuma, S; Kamoshita, N; Kawate, S; Kobayashi, I; Kobayashi, J; Makita, F; Nakagami, K; Ohya, T; Okabe, T; Sakamoto, I; Sato, Y; Sunose, Y; Takeyoshi, I; Tanahashi, Y; Tomizawa, N; Yamada, T; Yoshinari, D, 2011
)
0.91

Bioavailability

The bioavailability of oral idarubicin and of oral doxifluridine allows for their use in an oral 3 drug regimen. Because of the high bioavailability and low toxicity of oralDoxifLuridine we conducted this phase II trial to evaluate the feasibility, toxicity and activity of a home therapy.

ExcerptReferenceRelevance
" After a 700-mg/kg rectal dose, the terminal half-life was 430 min, the bioavailability was 30%, and the fraction of the dose recovered in 24-hr feces was 34%."( Absorption of 5'-deoxy-5-fluorouridine from colon.
Au, JL; Gunnarsson, LC, 1989
)
0.28
" UR did not alter the Cl of dFUR, but reduced the absorption rate of dFUR from the gastrointestinal tract and significantly reduced the absolute oral bioavailability of dFUR from 55."( Effect of uridine coadministration on 5'-deoxy-5-fluorouridine disposition in rats.
Au, JL; Bramer, SL; Wientjes, MG, 1988
)
0.27
" Because of the high bioavailability and low toxicity of oral doxifluridine we conducted this phase II trial to evaluate the feasibility, toxicity and activity of a home therapy with oral doxifluridine in elderly metastatic colorectal cancer patients."( Oral doxifluridine in elderly patients with metastatic colorectal cancer: a multicenter phase II study.
Barduagni, M; Bertuccelli, M; Calabresi, F; Carrai, M; Ceribelli, A; Cianci, C; De Marco, S; Falcone, A; Pfanner, E; Ricci, S, 1994
)
1.04
" The bioavailability of oral idarubicin and of oral doxifluridine allows for their use in an oral 3 drug regimen."( Phase II study of an oral combination of doxifluridine, prednimustine and idarubicin (FUPRIDA) for first line treatment of advanced breast cancer.
Alberto, P, 1993
)
0.8
" AcyT increased the maximal plasma concentration (Cmax) and apparent absorption rate constant (ka) of 5'-DFUR, as expected, but the increase in AUC (area under the curve) was not significant."( Modulation of the pharmacokinetics of 5'-deoxy-5-fluorouridine and 5-fluorouracil in rats by oral co-administration of acyclothymidine.
Fukushima, S; Hamada, A; Kawaguchi, T; Nakano, M; Saneyoshi, M; Shimizu, S, 1996
)
0.29
" The mean systemic bioavailability of oral dFUrd was 34-47%."( Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients.
De Bruijn, EA; Highley, MS; Maes, RA; Reeuwijk, HJ; Tjaden, UR; Van Der Heyden, SA; Van Oosterom, AT; Van Slooten, H, 1999
)
0.3
" The absorption rate of dFUR, analyzed by the Loo-Riegelman method, suggests that drug absorption took place in part by saturable mechanisms."( Disposition and availability of 5-fluorouracil prodrug 5'-deoxy-5-fluorouridine after oral administration in rats.
Au, JL, 1987
)
0.27
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" Average bioavailability was assessed by ANOVA."( Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations.
Baken, BC; Erlinghagen, V; Fuhr, U; Kubeš, V; Novotný, V; Peroutka, R; Queckenberg, C; Van Os, SH; Wargenau, M, 2015
)
0.42
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Treatment with doxifluridine at a dosage of 3000 mg/m2 given intravenously for 5 successive days at 3-week intervals led to 6 partial remissions (17%)

ExcerptRelevanceReference
" Dose-response curves for each agent indicate the following absolute potency: FUDR greater than FUR greater than ARA-C greater than 5-FU = bleomycin greater than DFUR."( Evaluation of antiproliferative agents using a cell-culture model.
Senderoff, RI; Smith, DR; Sokoloski, TD; Weber, PA, 1990
)
0.28
" Treatment with doxifluridine at a dosage of 3000 mg/m2 given intravenously for 5 successive days at 3-week intervals led to 6 partial remissions (17%)."( Phase II clinical trial of doxifluridine in patients with advanced ovarian cancer.
Neijt, JP; ten Bokkel Huinink, WW; van der Burg, ME; van Oosterom, AT; Vermorken, JB; Willemse, PH, 1991
)
0.92
" This was deemed due to the small dosage and a short duration of 5'-DFUR."( [A study on preoperative administration of doxifluridine in carcinoma of the colon and rectum].
Harada, T; Hirano, M; Kikkawa, H; Masuda, S; Matsu, T; Saito, H; Sakatoku, M; Tatsuzawa, T, 1990
)
0.54
"5'-DFUR was administered orally at 800 mg/day, for total dosage of 57."( [A resected case of gastric carcinoma with complete remission of Virchow's node metastasis by 5'-DFUR administration].
Fukuda, H; Kitahara, T; Nagamine, H; Nakaguchi, K; Nakano, Y; Onoe, K, 1990
)
0.28
" The optimal dosage for a phase II study was suggested to be less than 2,100 mg/body/day."( [Phase I study of 5'-deoxy-5-fluorouridine (5'-DFUR)].
Furue, H; Kanamaru, R; Kimura, K; Komita, T; Murakami, M; Nakao, I; Ohta, K; Saito, T; Wakui, A; Yokoyama, M, 1985
)
0.27
" The optimal daily dosage was considered to be 800-1,200 mg/body/day."( [Phase II study of 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with malignant cancer--a multi-institutional cooperative study].
Abe, O; Kimura, K; Kimura, T; Kurihara, M; Nakao, I; Niitani, H; Ohta, K; Saito, T; Urushizaki, I; Yoshida, Y, 1985
)
0.27
" The oral daily dosage of 5'-DFUR was 1,200 mg and that of tegafur was 800 mg, both drugs being administered every day for more than 4 weeks."( [A comparative study of 5'-DFUR and tegafur in recurrent breast cancer].
Abe, O; Ogawa, N; Taguchi, T; Terasawa, T; Tominaga, T; Yoshida, Y, 1985
)
0.27
"1% of cases; however, it was easily reduced by decreasing the dosage or discontinuing administration of the drug."( [Phase II study of 5'-DFUR in gastrointestinal and breast cancer].
Hayashi, K; Kitamura, M; Kosaki, G; Takahashi, I; Tominaga, T, 1985
)
0.27
"5'-DFUR was administered orally to advanced or recurrent cancer patients at a daily dosage of 600-1200 mg divided into 3 or 4 times a day."( [Clinical trial of 5'-deoxy-5-fluorouridine (5'-DFUR) in advanced cancer patients].
Imamura, Y; Irie, K; Nakamura, T; Suehiro, I; Yasutake, K; Yoshida, M; Yoshimura, Y, 1985
)
0.27
" The neurotoxicity was dose related, affecting 7 of 8 patients in the high dosage group and 3 of 9 patients in the low dosage group."( Wernicke-Korsakoff-like syndrome in patients with colorectal carcinoma treated with high-dose doxifluridine (5'-dFUrd).
Fosså, SD; Heier, MS, 1986
)
0.49
" Further pharmacological studies seem warranted to define the optimal dosage schedule and to obtain a better therapeutic index."( Phase II clinical evaluation of doxifluridine.
Armand, JP; Bastit, P; Cappelaere, P; Fargeot, P; Fumoleau, P; Hurteloup, P; Keiling, R; Kerbrat, P; Metz, R; Schraub, S, 1986
)
0.55
" This diarrhea, however, disappeared rapidly by decreasing the dosage or termination of treatment."( [A new anticancer drug, 5'-deoxy-5-fluorouridine (5'-DFUR)].
Tsukagoshi, S, 1987
)
0.27
"To investigate the optimal dosage schedule for 5'-deoxy-5-fluorouridine (5'-DFUR), a randomized comparative study was performed in patients with inoperable or advanced gastric cancer."( [Randomized comparison of continuous and intermittent oral administration of 5'-deoxy-5-fluorouridine in the treatment of advanced gastric cancer; a phase II trial by the Multi-institutional Cooperative Study Group].
Hasegawa, K; Hatta, Y; Kawachi, M; Kurihara, M; Niitani, H; Suwa, T; Taguchi, S; Tsuboi, E; Yasui, A; Yoshimori, K, 1987
)
0.27
"5'-DFUR was administered orally to recurrent breast cancer patients at a daily dosage of 1,200 mg given 3 times a day for more than 8 weeks."( [Clinical trial of 5'-DFUR in patients with recurrent breast cancer].
Komaki, K; Konishi, Y; Miki, H; Monden, Y; Morimoto, T; Ooshimo, K; Tanaka, T; Uomine, Y; Yamakawa, T, 1988
)
0.27
" The frequency of cerebellopathy may depend on the dosage and type of administration of the drug."( Neurological manifestations in a phase 2 study of 13 patients treated with doxyfluridine.
Fosså, SD; Heier, MS, 1985
)
0.27
" 5'-DFUR was administered three or four times a day at a daily dosage of 600 to 1200 mg."( [Clinical phase II study of 5'-DFUR for cancer of the digestive organs by a cooperative study group].
Gocho, Y; Ishitani, K; Kogo, Y; Kouda, K; Koyama, R; Matsuda, M; Nagai, T; Niitsu, Y; Saijo, N; Urushizaki, I, 1985
)
0.27
" 5'-DFUR (5'-deoxy-5-fluorouridine) was administered orally at 1,200 mg/day for 23 weeks, for a total dosage of 110."( [A case of gastric cancer in which long-term administration of 5'-deoxy-5-fluorouridine (5'-DFUR) proved effective].
Iwao, N; Koda, T; Kurahori, T; Miyaji, J; Okahisa, N; Sonoda, T; Sumi, S; Yanagimoto, H, 1987
)
0.27
" 5'-dFUrd was a more effective antitumor agent and was less toxic over a wide dosage range (50 to 400 mg/kg) than the other agents tested as measured by: (a) the ability to prevent gross development of inoculated tumor; (b) 45-day survival; and (c) weight change over the treatment period."( Metabolism and biological activity of 5'-deoxy-5-fluorouridine, a novel fluoropyrimidine.
Armstrong, RD; Diasio, RB, 1980
)
0.26
" At the 1st hr after dosing the 5-FU level in the small intestine was close to, but that in other tissues was much lower than, the 5-FU level in the tumor of both types."( Tissue distribution of 5'-deoxy-5-fluorouridine and derived 5-fluorouracil in tumor-bearing mice and rats.
Fukazawa, H; Hongu, Y; Ichihara, S; Shimizu, H; Suzuki, S, 1980
)
0.26
" Eleven out of 19 patients (58%; 95% CI:34-80%) showed a complete (2 cases) or partial (9 cases) response to this treatment, regardless of the 5dFUR dosage employed."( Dose-finding study of 5'-deoxy-5-fluorouridine in combination with fixed doses of cisplatin and L-folinic acid for the treatment of advanced or recurrent squamous cell carcinoma of the head and neck.
Biglietto, M; Carteni, G; Catalano, G; Comella, G; Comella, P; Della Vittoria Scarpati, M; Palmieri, G; Pandolfi, A; Stampino, CG,
)
0.13
"The treatment with 5'-dFUR was stopped at 5 g/m2, since this level corresponded to the maximum monthly dosage reported in the literature (36-38 g)."( A phase I safety study of doxifluridine and interferon-alpha-2a in patients with advanced neoplastic disease.
Antimi, M; Majoli, L; Minelli, M; Pandolfi, A; Papa, G; Stampino, CG, 1993
)
0.59
" Although the MTD was not reached, it can be stated that the dosage administered in this study could be explored in a larger trial."( A phase I safety study of doxifluridine and interferon-alpha-2a in patients with advanced neoplastic disease.
Antimi, M; Majoli, L; Minelli, M; Pandolfi, A; Papa, G; Stampino, CG, 1993
)
0.59
" In terms of ER stratification, ER(-) patients in the dosing groups showed increasing tendencies in S-phase and significant differences of G1- as well as G2+M phases."( [Influences of 5'-deoxy-5-fluorouridine (5'-DFUR) on cell cycle in patients with breast cancer].
Fujii, A; Hamano, K; Kamio, T; Katoh, T; Kimura, T; Muraki, H; Yamamoto, K, 1993
)
0.29
" The ratio of FBAL to 5-FU in Cmax and AUC after dosing of UFT was the lowest among these four test compounds."( [Comparison of pharmacokinetics of 5-FU and alpha-fluoro-beta-alanine, a metabolite of 5-FU, in plasma after administration of UFT, tegafur, 5-FU or doxifluridine to rats].
Hirakawa, Y; Kawaguchi, Y; Kuwata, K; Matsushima, E; Nagayama, S, 2000
)
0.51
" The combination showed better antitumor efficacy than the monotherapy of either agent in either dosing regimen."( Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
Fujimoto-Ouchi, K; Tanaka, Y; Tominaga, T, 2001
)
0.31
" It was repeated every 3 weeks, as long as possible, including dosage levels of 5 scheduled steps."( [A phase I study of docetaxel (TXT) and doxifluridine (5'-DFUR) combination therapy in patients with advanced and recurrent breast cancer].
Aoyama, H; Asaga, T; Iwase, H; Kimura, M; Mitsuyama, S; Nishimura, R; Tominaga, T, 2001
)
0.58
" The dosage of the oral clinical use for human cancer of 5-FU, HCFU, 5'-DFUR and UFT as tegafur (FT) is 200-300mg/d, 600mg/d, 800-1,200mg/d and 300-600mg/d respectively."( Plasma, intestine and tumor levels of 5-fluorouracil in mice bearing L1210 ascites tumor following oral administration of 5-fluorouracil, UFT (mixed compound of tegafur and uracil), carmofur and 5'-deoxy-5-fluorouridine.
Higashigawa, M; Kagawa, Y; Kakito, H; Kawasaki, H; Kojima, M; Ohkubo, T; Ooi, A; Sakurai, M, 2001
)
0.31
" Two months later a side effect of MPA, her body weight gain, was observed, and the dosage of MPA was reduced from 1,200 mg/day to 800 mg/day."( [A case of long surviving advanced recurrent breast cancer with multiple bone metastases responding to treatment with 5'-DFUR combined with MPA].
Otsuka, T; Tashiro, S; Terashima, Y, 2002
)
0.31
" Although the CDDP dosage had been reduced to 5 mg/week 1 year previously, the tumor was still reducing in size in November 2000."( Metastatic urothelial cancer showing an efficacy by low-dose cisplatin.
Hirata, H; Matsuyama, H; Yamakawa, G, 2002
)
0.31
" Administration of doxifluridine (5'-DFUR: Furtulon) (1,200 mg/day, 5 day continuous dosing followed by 2 day washout) and medroxyprogesterone acetate (MPA: Hysron H) (1,200 mg/day) was followed by chemotherapy consisting of intraarterial infusion of 100 mg of docetaxel (TXT: Taxotere), once monthly, via the left internal thoracic artery and left lateral thoracic artery."( [One case of locally advanced breast cancer in which multidisciplinary treatment, chiefly, therapy with preoperative intraarterial infusion of docetaxel (TXT), was successful].
Hara, A; Harada, T; Iwamoto, S; Izumi, N; Matsubara, C; Satake, K; Tsunematsu, I, 2002
)
0.64
" The present results have no clinical implications for the use of capecitabine and argue against the value of therapeutic drug monitoring for dosage adjustment."( Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
Blesch, KS; Burger, HU; Gieschke, R; Reigner, B; Steimer, JL, 2003
)
0.32
" The anti-tumor effective dosage of P5, P6 and their mixture, P5+P6, were obtained in dose-dependent manner."( Therapeutic effects of novel anti-tumor reagent, apoptosis inducing nucleosides from CD57+HLA-DRbright natural suppressor cell line on human gastric carcinoma-bearing SCID mice.
Guo, M; Jin, A; Mori, E; Mori, T; Qi, Y; Takasaki, S, 2004
)
0.32
"First, we determined the optimal dosing regimen in murine models."( Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer.
Fujimoto-Ouchi, K; Kato, T; Kikkawa, N; Mishima, H; Nishisho, I; Tanaka, Y; Tsujie, M; Tsujinaka, T; Yanagisawa, M, 2005
)
0.59
" A further six patients were added in order to confirm the safety of this dosage level, and no more DLTs except for grade 3 nausea in one patient were observed in the second cohort."( A phase I study of doxifluridine combined with weekly paclitaxel for metastatic gastric cancer.
Endo, S; Hidaka, S; Hirao, K; Hirasaki, S; Hyodo, I; Kajiwara, T; Kurita, A; Masumoto, T; Moriwaki, T; Nasu, J; Nishina, T; Tsuzuki, T, 2005
)
0.66
" The mean dosage per course of TXT was 58."( [Bi-weekly chemotherapy with medium-dose docetaxel for advanced and recurrent breast cancers (The 15th study of Keiji Breast Cancer Study Group)].
Fujii, K; Fujino, S; Higashide, S; Hori, T; Inamoto, T; Kan, N; Lee, CJ; Maruhashi, K; Mise, K; Mitsumori, M; Nishimura, S; Okamoto, M; Okamura, T; Sawai, S; Takemoto, Y; Yamauchi, A, 2005
)
0.33
" The significance of treatment dosage and duration was obvious when 5-DFUR and Tam cotreatment was observed to be antagonistic in 3-day cultures of a second MCF-7 subline and T47D cells."( Combination of 5-deoxy-5-fluorouridine and tamoxifen show cell-type specific antagonistic and cooperative effects on cytotoxicity in human mammary carcinoma cells.
Bollig, A; Du, QQ; Fan, ST; Liao, J; Sarkar, FH; Yu, B, 2005
)
0.33
" Only BILT significantly influenced the pharmacokinetics but this effect was not considered as relevant for dosing adjustment."( Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
Lokiec, F; Rezaí, K; Urien, S, 2005
)
0.33
" Although a traditional toxicity-based maximum tolerated dose was not achieved, the highest dosing cohort represented a biologically relevant dose of enzastaurin, on the basis of preclinical data and correlative pharmacodynamic biomarker assays of protein kinase Cbeta inhibition in peripheral blood mononucleocytes, in combination with a standard dose of capecitabine."( A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
Baldwin, J; Basche, M; Britten, CD; Camidge, DR; Darstein, C; Finn, RS; Gail Eckhardt, S; Gore, L; Holden, SN; Leong, S; Musib, L; O'Bryant, CL; Thornton, D, 2008
)
0.35
" Since the concomitant use of warfarin and the oral fluoropyrimidines was unavoidable in this case, the warfarin dosage was adjusted to keep INR within goal range (1."( Increased anticoagulant activity of warfarin used in combination with doxifluridine.
Genda, T; Hori, S; Miki, A; Nakajima, M; Satoh, H; Sawada, Y; Suehira, M, 2010
)
0.59
"To keep INR within goal range, the maintenance dosage of warfarin was reduced during the treatment with doxifluridine as well as capecitabine."( Increased anticoagulant activity of warfarin used in combination with doxifluridine.
Genda, T; Hori, S; Miki, A; Nakajima, M; Satoh, H; Sawada, Y; Suehira, M, 2010
)
0.81
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antimetaboliteA substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
pyrimidine 5'-deoxyribonucleosideA pyrimidine deoxyribonucleoside that is a pyrimidine ribonucleoside in which the hydroxy group at the 5' position is replaced by a hydrogen.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
Fluoropyrimidine Pathway, Pharmacokinetics248
Capecitabine Action Pathway58
Capecitabine Metabolism Pathway58

Protein Targets (33)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency43.64860.002541.796015,848.9004AID1347398
RAR-related orphan receptor gammaMus musculus (house mouse)Potency26.60320.006038.004119,952.5996AID1159521
TDP1 proteinHomo sapiens (human)Potency23.16210.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency18.83360.000714.592883.7951AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency3.16230.180013.557439.8107AID1460
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency10.66120.001022.650876.6163AID1224838; AID1224893
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency33.49150.001530.607315,848.9004AID1224821
farnesoid X nuclear receptorHomo sapiens (human)Potency33.48890.375827.485161.6524AID743220
estrogen nuclear receptor alphaHomo sapiens (human)Potency18.54110.000229.305416,493.5996AID743075; AID743077; AID743079
67.9K proteinVaccinia virusPotency28.18380.00018.4406100.0000AID720579
glucocerebrosidaseHomo sapiens (human)Potency0.35480.01268.156944.6684AID2101
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.02240.035520.977089.1251AID504332
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency42.561523.934123.934123.9341AID1967
importin subunit beta-1 isoform 1Homo sapiens (human)Potency0.81995.804836.130665.1308AID540253
snurportin-1Homo sapiens (human)Potency0.81995.804836.130665.1308AID540253
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency29.84700.000627.21521,122.0200AID743202
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency0.81995.804816.996225.9290AID540253
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency1.36350.004611.374133.4983AID624296; AID624297
M-phase phosphoprotein 8Homo sapiens (human)Potency0.79430.177824.735279.4328AID488949
lamin isoform A-delta10Homo sapiens (human)Potency0.84220.891312.067628.1838AID1487
Cellular tumor antigen p53Homo sapiens (human)Potency22.42090.002319.595674.0614AID651631; AID720552
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency0.79430.009610.525035.4813AID1479145
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency11.22021.000010.475628.1838AID1457
ATAD5 protein, partialHomo sapiens (human)Potency29.08100.004110.890331.5287AID493106
EWS/FLI fusion proteinHomo sapiens (human)Potency14.00720.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
arylsulfatase AHomo sapiens (human)Potency8.49211.069113.955137.9330AID720538
flap endonuclease 1Homo sapiens (human)Potency2.66790.133725.412989.1251AID588795
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency8.49210.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thymidylate kinaseMycobacterium tuberculosis H37RvKi560.00004.50008.500010.0000AID210904
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (132)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
nucleobase-containing compound metabolic processUridine phosphorylase 1Homo sapiens (human)
uridine catabolic processUridine phosphorylase 1Homo sapiens (human)
CMP catabolic processUridine phosphorylase 1Homo sapiens (human)
dCMP catabolic processUridine phosphorylase 1Homo sapiens (human)
cellular response to glucose starvationUridine phosphorylase 1Homo sapiens (human)
UMP salvageUridine phosphorylase 1Homo sapiens (human)
UMP catabolic processUridine phosphorylase 1Homo sapiens (human)
dTMP catabolic processUridine phosphorylase 1Homo sapiens (human)
dUMP catabolic processUridine phosphorylase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (37)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
uridine phosphorylase activityUridine phosphorylase 1Homo sapiens (human)
thymidine phosphorylase activityUridine phosphorylase 1Homo sapiens (human)
identical protein bindingUridine phosphorylase 1Homo sapiens (human)
deoxyuridine phosphorylase activityUridine phosphorylase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
nucleoplasmUridine phosphorylase 1Homo sapiens (human)
cytosolUridine phosphorylase 1Homo sapiens (human)
cytosolUridine phosphorylase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (192)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID138753Antitumor activity was determined for 7-day average percent weight change against P-388 leukemia in mice at a dose of 320 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID136489Antitumor activity was determined for median survival of mice against P-388 leukemia in mice at a dose of 80 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID137717Percent treated was determined after administration at 750 mg/kg orally1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID138867Antitumor activity was determined for 7-day average percent weight change against P-388 leukemia in mice at a dose of 640 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID119909Mortality rate was measured at a dose of 100 mg/kg1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Synthesis and biological activity of 5'-substituted 5-fluoropyrimidine nucleosides.
AID136479Antitumor activity was determined for median survival of mice against P-388 leukemia in mice at a dose of 320 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID135576Percent inhibition against M5076 mouse reticulum cell sarcoma after administration at 62.5 mg/kg orally on day 201993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID135575Percent inhibition against M5076 mouse reticulum cell sarcoma after administration at 500 mg/kg orally on day 201993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1131064Antitumor activity against mouse Sarcoma 180 cells allografted in CD1 mouse at 200 mg/kg, ip qd administered shortly post implantation continued for 8 days relative to vehicle-treated control1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides.
AID98644Antitumor activity against L1210 leukemia cells in mice at a dose of 100 mg/kg (ip) expressed as change in the body weight after 7 days1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Synthesis and biological activity of 5'-substituted 5-fluoropyrimidine nucleosides.
AID1131067Antitumor activity against mouse Sarcoma 180 cells allografted in CD1 mouse at 25 mg/kg, ip qd administered shortly post implantation continued for 8 days relative to vehicle-treated control1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID135569Percent inhibition against M5076 mouse reticulum cell sarcoma after administration at 250 mg/kg orally on day 201993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID136349Tested for 60-day survivors after administration at 500 mg/kg orally in M5076 mouse reticulum cell sarcoma1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID138746Antitumor activity was determined for 7-day average percent weight change against P-388 leukemia in mice at a dose of 160 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID137709Percent treated was determined after administration at 250 mg/kg orally1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID116827Percent increase in life span(ILS) was measured in mice at a dose of 100 mg/kg1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Synthesis and biological activity of 5'-substituted 5-fluoropyrimidine nucleosides.
AID139041Weight change in M5076 mouse reticulum cell sarcoma after administration at 500 mg/kg orally1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID128227Antitumor activity was determined for average 7-day weight change against P-388 leukemia in mice at a dose of 640 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID128239Antitumor activity was determined for average weight on day 1 against P-388 leukemia in mice at a dose of 160 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1131071Toxicity in mouse in po dosed CD1 mouse assessed as leukopenia administered once daily starting shortly post implantation continued for 8 days relative to vehicle-treated control1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides.
AID136501Antitumor activity was determined for survival range of mice against P-388 leukemia in mice at a dose of 320 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID139042Weight change in M5076 mouse reticulum cell sarcoma after administration at 62.5 mg/kg orally1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID128220Antitumor activity was determined for average 7-day weight change against P-388 leukemia in mice at a dose of 320 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID128257Antitumor activity was determined for average weight on day 1 against P-388 leukemia in mice at a dose of 80 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID215483Relative Vmax for interaction with Urd phosphorylase1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and interaction with uridine phosphorylase of 5'-deoxy-4',5-difluorouridine, a new prodrug of 5-fluorouracil.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID135577Percent inhibition against M5076 mouse reticulum cell sarcoma after administration at 750 mg/kg orally on day 201993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID43697Concentration required for the 50% inhibition of growth of CCRF-CEM human leukemia cells in culture1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Synthesis and biological activity of 5'-substituted 5-fluoropyrimidine nucleosides.
AID128247Antitumor activity was determined for average weight on day 1 against P-388 leukemia in mice at a dose of 320 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID136485Antitumor activity was determined for median survival of mice against P-388 leukemia in mice at a dose of 640 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID132213Percent increase in life span against P-388 leukemia in mice was determined at a dose of 80 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID309150Antitumor activity against human SW620 cells in nude mouse assessed as tumor volume on day 12 at 50 mg/kg, ip for 20 days2007Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19
Synthesis and biological evaluation of cinnamyl compounds as potent antitumor agents.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID136203Tested for 60-day survivors after administration at 125 mg/kg orally in M5076 mouse reticulum cell sarcoma1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1131070Antitumor activity against mouse Sarcoma 180 cells allografted in CD1 mouse at 3.12 to 800 mg/kg, ip qd administered shortly post implantation for 8 days relative to vehicle-treated control1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides.
AID136351Tested for 60-day survivors after administration at 750 mg/kg orally in M5076 mouse reticulum cell sarcoma1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID309151Antitumor activity against human SW620 cells in nude mouse assessed as tumor volume on day 14 at 50 mg/kg, ip for 20 days2007Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19
Synthesis and biological evaluation of cinnamyl compounds as potent antitumor agents.
AID210904Inhibitory activity against thymidine monophosphate kinase (TMPK) in Mycobacterium tuberculosis2003Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18
Thymidine and thymidine-5'-O-monophosphate analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase.
AID211077Susceptibility to thymidine phosphorylase (ThdPase) at a substrate concentration of 1.0 mM2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine.
AID116829Percent increase in life span(ILS) was measured in mice at a dose of 250 mg/kg1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Synthesis and biological activity of 5'-substituted 5-fluoropyrimidine nucleosides.
AID25143Half life at pH 11988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and interaction with uridine phosphorylase of 5'-deoxy-4',5-difluorouridine, a new prodrug of 5-fluorouracil.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1309496Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 6 to 24 hrs by counting chamber analysis2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Doxifluridine-conjugated 2-5A analog shows strong RNase L activation ability and tumor suppressive effect.
AID136507Antitumor activity was determined for survival range of mice against P-388 leukemia in mice at a dose of 640 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID139035Weight change in M5076 mouse reticulum cell sarcoma after administration at 250 mg/kg orally1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID98645Antitumor activity against L1210 leukemia cells in mice at a dose of 150 mg/kg (ip) expressed as change in the body weight after 7 days1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Synthesis and biological activity of 5'-substituted 5-fluoropyrimidine nucleosides.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1131072Toxicity in mouse in po dosed CD1 mouse assessed as change in body weight administered once daily starting shortly post implantation continued for 8 days relative to vehicle-treated control1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides.
AID139043Weight change in M5076 mouse reticulum cell sarcoma after administration at 750 mg/kg orally1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID132202Percent increase in life span against P-388 leukemia in mice was determined at a dose of 320 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID128253Antitumor activity was determined for average weight on day 1 against P-388 leukemia in mice at a dose of 640 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID98552Concentration required for the 50% inhibition of growth of L1210 mouse leukemia cells in culture1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Synthesis and biological activity of 5'-substituted 5-fluoropyrimidine nucleosides.
AID98340Inhibition of cell growth of L1210 mouse Leukemia cells1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and interaction with uridine phosphorylase of 5'-deoxy-4',5-difluorouridine, a new prodrug of 5-fluorouracil.
AID138871Antitumor activity was determined for 7-day average percent weight change against P-388 leukemia in mice at a dose of 80 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID98646Antitumor activity against L1210 leukemia cells in mice at a dose of 250 mg/kg (ip) expressed as change in the body weight after 7 days1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Synthesis and biological activity of 5'-substituted 5-fluoropyrimidine nucleosides.
AID137716Percent treated was determined after administration at 62.5 mg/kg orally1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID215482Kinetic constant for interaction with Urd phosphorylase from Lewis lung carcinoma1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and interaction with uridine phosphorylase of 5'-deoxy-4',5-difluorouridine, a new prodrug of 5-fluorouracil.
AID136494Antitumor activity was determined for survival range of mice against P-388 leukemia in mice at a dose of 160 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID1131066Antitumor activity against mouse Sarcoma 180 cells allografted in CD1 mouse at 50 mg/kg, ip qd administered shortly post implantation continued for 8 days relative to vehicle-treated control1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides.
AID136340Antitumor activity was determined for median survival of mice against P-388 leukemia in mice at a dose of 160 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID309149Antitumor activity against human SW620 cells in nude mouse assessed as tumor volume on day 9 at 50 mg/kg, ip for 20 days2007Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19
Synthesis and biological evaluation of cinnamyl compounds as potent antitumor agents.
AID309148Antitumor activity against human SW620 cells in nude mouse assessed as tumor volume on day 7 at 50 mg/kg, ip for 20 days2007Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19
Synthesis and biological evaluation of cinnamyl compounds as potent antitumor agents.
AID1131068Antitumor activity against mouse Sarcoma 180 cells allografted in CD1 mouse at 12.5 mg/kg, ip qd administered shortly post implantation continued for 8 days relative to vehicle-treated control1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides.
AID128232Antitumor activity was determined for average 7-day weight change against P-388 leukemia in mice at a dose of 80 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID25151Half life at pH 7.5; Not detectable hydrolysis after 7 days1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and interaction with uridine phosphorylase of 5'-deoxy-4',5-difluorouridine, a new prodrug of 5-fluorouracil.
AID128081Antitumor activity was determined for average 7-day weight change against P-388 leukemia in mice at a dose of 160 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID136206Tested for 60-day survivors after administration at 250 mg/kg orally in M5076 mouse reticulum cell sarcoma1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID309147Antitumor activity against human SW620 cells in nude mouse assessed as tumor volume on day 5 at 50 mg/kg, ip for 20 days2007Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19
Synthesis and biological evaluation of cinnamyl compounds as potent antitumor agents.
AID137582Percent treated was determined after administration at 125 mg/kg orally1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID119910Mortality rate was measured at a dose of 150 mg/kg1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Synthesis and biological activity of 5'-substituted 5-fluoropyrimidine nucleosides.
AID136512Antitumor activity was determined for survival range of mice against P-388 leukemia in mice at a dose of 80 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID1131065Antitumor activity against mouse Sarcoma 180 cells allografted in CD1 mouse at 100 mg/kg, ip qd administered shortly post implantation continued for 8 days relative to vehicle-treated control1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides.
AID136350Tested for 60-day survivors after administration at 62.5 mg/kg orally in M5076 mouse reticulum cell sarcoma1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID132195Percent increase in life span against P-388 leukemia in mice was determined at a dose of 160 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID116828Percent increase in life span(ILS) was measured in mice at a dose of 150 mg/kg1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Synthesis and biological activity of 5'-substituted 5-fluoropyrimidine nucleosides.
AID135566Percent inhibition against M5076 mouse reticulum cell sarcoma after administration at 125 mg/kg orally on day 201993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID132208Percent increase in life span against P-388 leukemia in mice was determined at a dose of 640 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID98673Evaluated for cytotoxicity against L1210 mouse leukemia cells1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and in vivo antitumor activity of potential 5-fluorouracil prodrugs.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID139032Weight change in M5076 mouse reticulum cell sarcoma after administration at 125 mg/kg orally1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID137715Percent treated was determined after administration at 500 mg/kg orally1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID119911Mortality rate was measured at a dose of 250 mg/kg1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Synthesis and biological activity of 5'-substituted 5-fluoropyrimidine nucleosides.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (707)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990134 (18.95)18.7374
1990's230 (32.53)18.2507
2000's248 (35.08)29.6817
2010's81 (11.46)24.3611
2020's14 (1.98)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.88 (24.57)
Research Supply Index6.81 (2.92)
Research Growth Index4.50 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials145 (19.15%)5.53%
Trials0 (0.00%)5.53%
Reviews34 (4.49%)6.00%
Reviews0 (0.00%)6.00%
Case Studies168 (22.19%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other410 (54.16%)84.16%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Dose Escalating Study of Yttrium 90 Microspheres (TheraSphere) With Capecitabine (Xeloda) for Intrahepatic Cholangiocarcinoma or Metastatic Disease to the Liver [NCT00858429]Phase 118 participants (Actual)Interventional2009-04-01Completed
Prospective Controlled Randomized Comparative Study About Quality of Life (QoL), Immunomodulation and Safety of Adjuvant Mistletoe Treatment in Patients With Gastric Carcinoma Receiving Chemotherapy After Operation [NCT01401075]Phase 432 participants (Actual)Interventional2006-03-31Completed
A Phase III Randomized Controlled Trial of Adjuvant Chemotherapy for Advanced Gastric Adenocarcinoma [NCT00296335]Phase 3855 participants (Actual)Interventional2002-02-28Completed
A Phase III Randomized Controlled Trial of Adjuvant Chemotherapy for Gastric Adenocarcinoma: Mitomycin and Doxifluridine Versus Intraperitoneal Chemotherapy and Mitomycin, Doxifluridine, and Cisplatin [NCT00296322]Phase 3528 participants (Actual)Interventional2001-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00296322 (3) [back to overview]Overall Survival
NCT00296322 (3) [back to overview]Relapse-free Survival
NCT00296322 (3) [back to overview]Toxicity Profile (According to NCI CTC Version 2.0)
NCT00296335 (3) [back to overview]Overall Survival Rate
NCT00296335 (3) [back to overview]Relapse-free Survival Rate
NCT00296335 (3) [back to overview]Number of Patients With Adverse Events

Overall Survival

(NCT00296322)
Timeframe: 3 years

Interventionpercentage of participants (Number)
Mitomycin and Short-term Fluoropyrimidine59.6
iceMFP71.2

[back to top]

Relapse-free Survival

(NCT00296322)
Timeframe: 3 years

Interventionpercentage of participants (Number)
Mitomycin and Short-term Fluoropyrimidine50.0
iceMFP60.2

[back to top]

Toxicity Profile (According to NCI CTC Version 2.0)

Because safety profile in oncology study is evaluated for each toxicity, it is impossible to present the overall patient number. Instead, we presented the number of patients who declined study therapy due to adverse events or patient will. (NCT00296322)
Timeframe: up to 1 year

Interventionparticipants (Number)
Mitomycin and Short-term Fluoropyrimidine13
iceMFP30

[back to top]

Overall Survival Rate

Overall survival rate at 3 years was defined as the proportion of patients who were alive at 3 years after surgery. (NCT00296335)
Timeframe: 3 years

Interventionpercentage of participants (Number)
Mitomycin Plus Short-term Fluoropyrimidine76.9
Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati73.1

[back to top]

Relapse-free Survival Rate

"Relapse-free survival at 3 years was defined as the proportion of patients who did not show an evidence of disease recurrence after 3 years of surgery.~Relapse was defined as any new tumor lesion." (NCT00296335)
Timeframe: 3 years

Interventionpercentage of participants (Number)
Mitomycin Plus Short-term Fluoropyrimidine67.0
Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati64.9

[back to top]

Number of Patients With Adverse Events

Per National Cancer Institute Common Toxicity Criteria version 2.0, up to 3 years (NCT00296335)
Timeframe: Up to 3 years

,
Interventionparticipants (Number)
NeutropeniaAnemiaThrombocytopeniaFatigueDiarrheaNauseaVomiting
Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati387413156391288371160
Mitomycin Plus Short-term Fluoropyrimidine262393101343219293104

[back to top]